Literature DB >> 30796023

Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy.

Naveen Pemmaraju1, Hagop Kantarjian1, Loretta Nastoupil2, Megan Dupuis1, Lisa Zhou1, Sherry Pierce1, Keyur P Patel3, Lucia Masarova1, Jorge Cortes1, Srdan Verstovsek1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30796023      PMCID： PMC6634962          DOI： 10.1182/blood-2019-01-897637

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  19 in total

1.  Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia.

Authors:  Koichi Takahashi; Naveen Pemmaraju; Paolo Strati; Graciela Nogueras-Gonzalez; Jing Ning; Carlos Bueso-Ramos; Rajyalakshmi Luthra; Sherry Pierce; Jorge Cortes; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Blood       Date:  2013-07-29       Impact factor: 22.113

2.  Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience.

Authors:  Lucia Masarova; Mohamad Cherry; Kate J Newberry; Zeev Estrov; Jorge E Cortes; Hagop M Kantarjian; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2015-09-25

3.  A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database.

Authors:  Andrew M Brunner; Gabriela Hobbs; Marla M Jalbut; Donna S Neuberg; Amir T Fathi
Journal:  Leuk Lymphoma       Date:  2015-08-19

4.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Authors:  Alessandro M Vannucchi; Jean Jacques Kiladjian; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Ruben Mesa; Shui He; Mark M Jones; William Garrett; Jingjin Li; Ulrich Pirron; Dany Habr; Srdan Verstovsek
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

5.  Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study.

Authors:  Henrik Frederiksen; Dóra Körmendiné Farkas; Christian Fynbo Christiansen; Hans Carl Hasselbalch; Henrik Toft Sørensen
Journal:  Blood       Date:  2011-10-28       Impact factor: 22.113

6.  Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients.

Authors:  Anna Ravn Landtblom; Hannah Bower; Therese M-L Andersson; Paul W Dickman; Jan Samuelsson; Magnus Björkholm; Sigurdur Yngvi Kristinsson; Malin Hultcrantz
Journal:  Leukemia       Date:  2018-01-30       Impact factor: 11.528

7.  Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome.

Authors:  Lucia Masarova; Kate J Newberry; Sherry A Pierce; Zeev Estrov; Jorge E Cortes; Hagop M Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2015-05-12       Impact factor: 3.156

8.  Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review.

Authors:  Monia Marchetti; Alessandra Carobbio; Enrica Capitoni; Tiziano Barbui
Journal:  Am J Hematol       Date:  2018-02-10       Impact factor: 10.047

9.  Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis.

Authors:  Helna Pettersson; Håvar Knutsen; Erik Holmberg; Björn Andréasson
Journal:  Eur J Haematol       Date:  2014-07-24       Impact factor: 2.997

10.  Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.

Authors:  Claire N Harrison; Adam J Mead; Anesh Panchal; Sonia Fox; Christina Yap; Emmanouela Gbandi; Aimee Houlton; Samah Alimam; Joanne Ewing; Marion Wood; Frederick Chen; Jason Coppell; Nicki Panoskaltsis; Steven Knapper; Sahra Ali; Angela Hamblin; Robyn Scherber; Amylou C Dueck; Nicholas C P Cross; Ruben Mesa; Mary Frances McMullin
Journal:  Blood       Date:  2017-08-09       Impact factor: 22.113
View more
  12 in total

Review 1.  The Rationale for Immunotherapy in Myeloproliferative Neoplasms.

Authors:  Lucia Masarova; Prithviraj Bose; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

2.  Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.

Authors:  Margherita Maffioli; Toni Giorgino; Barbara Mora; Alessandra Iurlo; Elena Elli; Maria Chiara Finazzi; Marianna Caramella; Elisa Rumi; Maria Cristina Carraro; Nicola Polverelli; Mariella D'Adda; Simona Malato; Marianna Rossi; Alfredo Molteni; Alessandro Vismara; Cinzia Sissa; Francesco Spina; Michela Anghilieri; Daniele Cattaneo; Rossella Renso; Marta Bellini; Maria Luisa Pioltelli; Chiara Cavalloni; Daniela Barraco; Raffaella Accetta; Lorenza Bertù; Matteo Giovanni Della Porta; Francesco Passamonti
Journal:  Blood Adv       Date:  2019-11-12

3.  [Management of inflammatory rheumatic diseases during and after malignancies].

Authors:  Marc Schmalzing
Journal:  Z Rheumatol       Date:  2022-07-07       Impact factor: 1.372

Review 4.  Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.

Authors:  Giuseppe G Loscocco; Alessandro M Vannucchi
Journal:  Int J Hematol       Date:  2022-03-29       Impact factor: 2.490

5.  Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis.

Authors:  Douglas Tremblay; Amber King; Lihua Li; Erin Moshier; Alexander Coltoff; Anita Koshy; Marina Kremyanskaya; Ronald Hoffman; Michael J Mauro; Raajit K Rampal; John Mascarenhas
Journal:  Leuk Lymphoma       Date:  2019-11-12

Review 6.  Management of challenging myelofibrosis after JAK inhibitor failure and/or progression.

Authors:  Robyn M Scherber; Ruben A Mesa
Journal:  Blood Rev       Date:  2020-05-30       Impact factor: 8.250

Review 7.  Overview of Myeloproliferative Neoplasms: History, Pathogenesis, Diagnostic Criteria, and Complications.

Authors:  Douglas Tremblay; Abdulraheem Yacoub; Ronald Hoffman
Journal:  Hematol Oncol Clin North Am       Date:  2021-01-26       Impact factor: 3.722

8.  Burkitt leukemia with precursor B-cell features that developed after ruxolitinib treatment in a patient with hydroxyurea-refractory JAK2V617F-myeloproliferative neoplasm.

Authors:  Katsuhiro Fukutsuka; Futoshi Iioka; Fumiyo Maekawa; Miho Nakagawa; Chiyuki Kishimori; Masahiko Hayashida; Shunsuke Tagawa; Takashi Akasaka; Gen Honjo; Hitoshi Ohno
Journal:  J Clin Exp Hematop       Date:  2021-05-14

Review 9.  Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group.

Authors:  Vikas Gupta; Sonia Cerquozzi; Lynda Foltz; Christopher Hillis; Rebecca Devlin; Mahmoud Elsawy; Kuljit Grewal; Caroline Hamm; Caroline McNamara; Shireen Sirhan; Brian Leber
Journal:  JCO Oncol Pract       Date:  2020-03-05

Review 10.  Standard care and investigational drugs in the treatment of myelofibrosis.

Authors:  Daniela Barraco; Margherita Maffioli; Francesco Passamonti
Journal:  Drugs Context       Date:  2019-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.